Observing the effects of liposomal doxorubicin in breast cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the efficacy and safety of a regimen containing liposomal doxorubicin for patients undergoing postoperative adjuvant treatment for breast cancer. It includes female participants aged 18-75 years who have been diagnosed with primary breast cancer and are receiving this specific chemotherapy regimen. The study will monitor various health parameters and patient outcomes to gather data on the treatment's effectiveness and safety profile.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Female, aged 18-75 years;
2. Primary breast cancer diagnosed histopathologically;
3. Adjuvant chemotherapy regimens include liposomal doxorubicin;
4. ECoG PS score: 0-1 points;
5. Left ventricular ejection fraction (LVEF) ≥ 55%;
6. Estimated survival ≥ 6 months;
7. Major organ function is normal, i.e. meets the following criteria:

   ① And white blood cells ≥ 4.0 × 10 9 / L, neutrophil count (ANC) ≥ 1.5 × 10 9 /L；② Platelets ≥ 100 × 10 9 /L；③ And hemoglobin ≥ 10 g / dl; ④ Serum creatinine ≤ 1.5 × ⑤ the upper limit of normal (ULN) Mmol / L and aspartate transaminase (AST) ≤ 2.5

   × ULN；⑥ Alanine transaminase (ALT) ≤ 2.5 × ULN；⑦ Total bilirubin ≤ 1.5 × ULN；⑧ Serum creatinine ≤ 1.5 × ULN；
8. Subjects voluntarily join this study, sign the informed consent form, have good compliance and cooperate with follow-up.

Exclusion Criteria:

1. Pregnant, lactating patients;
2. Breast cancer has been found to have distant metastasis;
3. Those with peripheral nervous system disorders caused by the disease or with a history of significant mental disorders and central nervous system disorders;
4. Those with severe infection or active peptic ulcer requiring treatment;
5. Allergic to chemotherapy drugs;
6. Cancer free period less than 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix;
7. Severe liver disease (e.g., cirrhosis, etc.), renal disease, respiratory disease, or uncontrolled diabetes;
8. Patients who are participating in other clinical trials or within a month.

Where it's running

• Second Affiliate Hospital of Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Xiaochen Wang, Dr.
• Email: wangxiaochen@zju.edu.cn
• Phone: +86 13958161286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chemotherapy sensitivity-guided Culmerciclib combo for HR+/HER2- breast cancer before surgery

  This trial tests whether adding Culmerciclib to chemotherapy before surgery can help people with HR+/HER2- breast cancer who don’t respond to initial TAC treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07900516

• Compare SGLT-2 inhibitors vs DPP-4 inhibitors to prevent heart damage from doxorubicin in women with breast cancer

  This study tests whether a diabetes drug class (SGLT-2 inhibitors) or another (DPP-4 inhibitors) can help protect the heart of Egyptian women with breast cancer who are receiving doxorubicin chemotherapy.

  Recruiting Phase 4 Tanta University · Tanta, Elgharbeya · NCT07436663

• Using corticosteroids to reduce hand–foot skin reactions from liposomal doxorubicin

  This study will test whether giving corticosteroids around doses of liposomal doxorubicin can reduce painful hand–foot skin reactions in people with breast cancer receiving AC chemotherapy.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07362914

• Dapagliflozin to prevent heart damage from doxorubicin in breast cancer

  This trial will test if taking dapagliflozin can prevent heart damage in adults with early-stage breast cancer who are receiving doxorubicin chemotherapy.

  Recruiting Phase 2 Tanta University · Alexandria, Bab Sharqi · NCT06427226

• Comparing two treatment regimens for HER-2 positive breast cancer

  This study is testing two different treatment plans for people with HER-2 positive breast cancer to see which one works better before surgery.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guandong, Guangdong · NCT05159193

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.